A Phase 1, Open-label, Single-Dose Study to Investigate the Pharmacokinetics of DSP-6952 in Healthy Elderly and Young Males and Females

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225002

Enrollment

Registered

2020-01-06

Start date

2017-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Elderly and Young Males and Females

Interventions

investigational material(s) Generic name etc : DSP-6952 INN of investigational material : minesapride Therapeutic category code : 2-- Agents affecting individual organs Dosage and Administration for I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy males and females who are aged >= 65 and = 20 and < 40 years in case of young subjects at informed consent etc.

Exclusion criteria

Exclusion criteria: Subjects with a history of any significant disease such as cardiovascular, hepatic, renal, endocrine, gastrointestinal, hematological, respiratory, central nervous system or psychoneurological disease that is inappropriate for participation in this study in the opinion of the Investigator etc.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics DSP-6952 pharmacokinetic parameters	—

Secondary

Measure	Time frame
safety Adverse events, adverse drug reactions, laboratory tests, vital signs, and 12-lead electrocardiography	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026